Subscribe
lilly-logo-1
23 August 2013Americas

Eli Lilly bids to stop generics cutting Alimta exclusivity

Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
22 December 2020   The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
22 December 2020   The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).

More on this story

Americas
Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
22 December 2020   The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility